fda compounding semaglutide enforcement 2025 news What Patients Need to Know About the GLP-1 Policy Changes 4-3-2026 💔❤️‍🩹👹, xoxo reta rat,

This is a common tactic: The 1-month option exists, but it is priced to feel not worth it. The 3-month and 6-month options are framed as the smart choice

The more signaling pathways an active ingredient influences, the more relevant controlled clinical trial data, long-term observation, and regulatory review become

Unfortunately, both carrying excess weight and using GLP-1 medications for weight loss carry a stigma

The regulatory and supply landscape for retatrutide and semaglutide could not be more different right now, and these practical realities will determine which option is available to most people for the foreseeable future

Nearly half of participants lost more than 30% of their body weight, with some severe obesity patients exceeding 30% weight loss after two years of continuous treatment

However, retatrutide is still not FDA approved and cannot be prescribed or purchased